Literature DB >> 1198543

Proceedings: A more uniform measurement of factor VIII inhibitors.

C K Kasper, L Aledort, D Aronson, R Counts, J R Edson, J van Eys, J Fratantoni, D Green, J Hampton, M Hilgartner, P Levine, J Lazerson, C McMillan, J Penner, S Shapiro, N R Shulman.   

Abstract

Mesh：

Substances：

Year:  1975        PMID： 1198543

Source DB:  PubMed          Journal:  Thromb Diath Haemorrh        ISSN： 0340-5338


× No keyword cloud information.
  91 in total

1.  HLA-DR-restricted T-cell responses to factor VIII epitopes in a mild haemophilia A family with missense substitution A2201P.

Authors:  R A Ettinger; E A James; W W Kwok; A R Thompson; K P Pratt
Journal:  Haemophilia       Date:  2010-05       Impact factor: 4.287

2.  Rationale for a randomized controlled trial comparing two prophylaxis regimens in adults with severe hemophilia A: the Hemophilia Adult Prophylaxis Trial.

Authors:  Margaret V Ragni
Journal:  Expert Rev Hematol       Date:  2011-10       Impact factor: 2.929

3.  Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs.

Authors:  M W Nolte; T C Nichols; J Mueller-Cohrs; E P Merricks; I Pragst; S Zollner; G Dickneite
Journal:  J Thromb Haemost       Date:  2012-08       Impact factor: 5.824

4.  Quantitation of anti-factor VIII antibodies in human plasma.

Authors:  Jolanta Krudysz-Amblo; Behnaz Parhami-Seren; Saulius Butenas; Kathleen E Brummel-Ziedins; Edward D Gomperts; Georges E Rivard; Kenneth G Mann
Journal:  Blood       Date:  2009-01-14       Impact factor: 22.113

5.  Anti-CD3 antibodies modulate anti-factor VIII immune responses in hemophilia A mice after factor VIII plasmid-mediated gene therapy.

Authors:  Baowei Peng; Peiqing Ye; David J Rawlings; Hans D Ochs; Carol H Miao
Journal:  Blood       Date:  2009-09-21       Impact factor: 22.113

6.  Enhancing therapeutic efficacy of in vivo platelet-targeted gene therapy in hemophilia A mice.

Authors:  Xuefeng Wang; Richard Y Fu; Chong Li; Chun-Yu Chen; Jenni Firrman; Barbara A Konkle; Junping Zhang; Lei Li; Weidong Xiao; Mortimer Poncz; Carol H Miao
Journal:  Blood Adv       Date:  2020-11-24

7.  Long-term correction of hemophilia A mice following lentiviral mediated delivery of an optimized canine factor VIII gene.

Authors:  J M Staber; M J Pollpeter; C-G Anderson; M Burrascano; A L Cooney; P L Sinn; D T Rutkowski; W C Raschke; P B McCray
Journal:  Gene Ther       Date:  2017-09-14       Impact factor: 5.250

8.  Factor VIII inhibitors in hemophilia A: rationale and latest evidence.

Authors:  Char Witmer; Guy Young
Journal:  Ther Adv Hematol       Date:  2013-02

9.  Non-classical anti-factor VIII C2 domain antibodies are pathogenic in a murine in vivo bleeding model.

Authors:  S L Meeks; J F Healey; E T Parker; R T Barrow; P Lollar
Journal:  J Thromb Haemost       Date:  2009-01-24       Impact factor: 5.824

Review 10.  B-cell and T-cell epitopes in anti-factor VIII immune responses.

Authors:  Kathleen P Pratt; Arthur R Thompson
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.